AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04014621 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SPG stimulation
Description: The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
Study NCT04014621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SPG stimulation
Description: The BrainsGate Ischemic Stroke System (ISS) consists of an implantable neurostimulator designed to deliver electrical stimulation to the sphenopalatine ganglion (SPG) and/or nerves within the greater palatine canal and pterygopalatine fossa.
Study NCT03577392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin + capecitabine (XELOX chemotherapy)
Description: Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
Study NCT03577392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin + capecitabine (XELOX chemotherapy)
Description: Oxaliplatin(130mg/m2 over 2h)was intravenously administated for at least 2h on day 1. Capecitabine(1000mg/m2 twice daily)was oral administrated from the evening of day 1 to the morning of day 15.
Study NCT03577392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rebombniant human endostatin
Description: Endostar is a recombinat human endostatin with antiangiogenic properties that has been useful in treating a wide range of cancers and shows promise for use in combination treatment for advanced colorectal cancer. The dose of Recombinant human endostatin on day -5 was calculated according to the patients's body surface area, to provide a CIV 7 days' dose in physiological saline to 240mL volume.
Study NCT01342549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valproate
Description: 250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
Study NCT01342549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 25mg per day, taken by mouth for 7 days, then 50mg per day
Study NCT01206686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning Prompt
Description: Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
Study NCT01206686 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default Appointment
Description: Patients were given a suggested date and time for receiving a flu shot.
Study NCT01206686 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
Study NCT04700956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: primary abdominal closure
Description: The linea alba will be closed to a ratio of 5mm / 5mm. Only the fascia will be sutured ; fat or muscle tissue will be avoided. Subcutaneous tissue will be closed with polyglactin 3/0 suture. The skin will be closed with a stapler.
Study NCT04700956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: abdominal closure with prophylactic mesh
Description: After the fascia was closed with the same method, 5 cm of subcutaneous tissue will be dissected around the incision. The mesh will be placed in the supra-aponeurotic area (onlay) to a distance of laterally and cranial-caudally 5 cm from the fascia margins. The mesh used will be partially absorbable, light and large porous. After this procedure, the borders of the mesh will be fixed circumferentially on the abdominal wall using polypropylene suture to prevent the intestines from herniating on the mesh. Two subcutaneous drainage catheters will be placed in all patients with mesh.
Study NCT00591669 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Definity
Description: We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
Study NCT00591669 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Definity
Description: We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
Study NCT04641949 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Description: LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
Study NCT04641949 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Lower body negative pressure (LBNP)
Description: LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia. LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min. LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
Study NCT01740544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Description: Cathodal tDCS applied over the right PPC
Study NCT01740544 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham tDCS
Description: Sham tDCS applied over the right PPC
Study NCT01536704 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine (4 mg)
Description: 4 mg nicotine lozenge in two formulations
Study NCT02015845 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Accuvein
Study NCT02015845 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Routine technique
Description: Placement of peripheral intravenous catheters using the routine technique
Study NCT03190902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attention Processing Training program (APT)
Study NCT03190902 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nonspecific computer training (n-ST)
Study NCT02542631 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bolus Insulin Patch (Calibra Finesse)
Study NCT02542631 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Pen (Novo-Nordisk FlexPen®)
Study NCT02144441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glargine and aspart
Description: Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
Study NCT01536704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg)
Description: 4 mg nicotine lozenge in two formulations
Study NCT04353050 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Non-invasive adhesive system (patch)
Description: The already registered on the market adhesive skin patch will be applied and removed for several times on the pigmented skin (or mucosal) lesion just before the preplanned excisional biopsy after local anaesthesia have been already administered. Excisional biopsy and local anaesthesia are not the part of this study and will be carried out according to local practice
Study NCT01539252 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single dialyzer
Description: Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
Study NCT01539252 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two dialyzers
Description: Hemodialysis treatment using a two Baxter dialyzers in parallel.
Study NCT03493256 — intervention group
Intervention type: OTHER
Intervention: exposure to type 2 neurological complications
Description: exposure to postoperative cognitive dysfunction (POCD) or postoperative delirium (POD), or both concurrently.
Study NCT01492920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acetyl-L-Carnitine Hydrochloride
Description: Given orally
Study NCT01492920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT01492920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01492920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01492920 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT01492920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02352870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerised Cognitive Behavioural Therapy
Description: Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
Study NCT02352870 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerised Cognitive Behavioural Therapy
Description: Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
Study NCT02352870 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone support
Description: Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
Study NCT02248883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV low
Study NCT02248883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02248883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Study NCT02248883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPV high
Study NCT02248883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV
Study NCT04683016 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Patients will be asked two sets of questions:~* questionnaire about their perception of periodontal disease (Brief Illness Perception Questionnaire; 9 questions, answers will be registered on a scale of 0 to 10);~* Oral Health Impact Profile 14 (OHIP-14) questionnaire.~All these two sets of questions will be asked before and after non surgical periodontal therapy
Study NCT01415102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 1: 50 ug
Study NCT01415102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study NCT01415102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study NCT01415102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study NCT01415102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Inhaled
Study NCT01415102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study NCT01415102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study NCT01415102 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05212372
Description: Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
Study NCT01881984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ravicti
Description: Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
Study NCT03776149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
Study NCT03776149 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Black currant juice
Description: Following randomization on day 1, subjects will consume either the nitrate or nitrate-free beverage for 7 days with outcome measurements performed on day 7. Following a 7 day washout, subjects will then consume the crossover beverage for 7 days with outcome measures performed on day 21.
Study NCT03846583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Tucatinib is a drug that inhibits human epidermal growth factor receptor 2 (HER-2) protein, which is a protein expressed in the cancer cells. By inhibiting this protein, tucatinib may help stop or reduce the growth of the tumor
Study NCT03846583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
Study NCT03846583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: • Trastuzumab is called a targeted therapy because it works by attaching itself to specific receptors on the surface of breast cancer cells, known as HER2 receptors. When Trastuzumab attaches to HER2 receptors, the signals that tell the cells to grow are blocked and the cancer cell may be marked for destruction by the immune system.
Study NCT03846583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aromatase Inhibitor
Description: These drugs act by lowering the amount of estrogen produced by the body by blocking an enzyme called aromatase
Study NCT05494476 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: implant insertion
Description: after flap detachment, implant bed will be prepared with twist-drill, implant will be inserted according to randomization (1 or 2 mm under bone)
Study NCT02220062 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-CPN
Description: After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5\~10cc ethanol would be performed as bilateral injections at the celiac trunk.
Study NCT02220062 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EUS-CGN
Description: First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2\~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
Study NCT02210845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised exercise
Description: Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
Study NCT02210845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financially incentivized weight Loss
Description: Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
Study NCT02210845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care at BCDiabetes
Description: usual care dictated by GCP at BCDiabetes.ca
Study NCT04472676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3473329
Description: Administered orally.
Study NCT04472676 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study NCT04472676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.
Study NCT03958292 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IODIM
Description: Eye drops containing polyvinylpyrrolidone-Iodine (PVP-Iodine), hyaluronic acid and triglycerides
Study NCT00442871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag
Description: eltrombopag 50 mg oral
Study NCT00394563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 10 mcg/kg
Study NCT03138720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Protein Bound (Abraxane)
Description: Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
Study NCT03950726 — intervention group
Intervention type: PROCEDURE
Intervention: ileocolic resection
Description: Ileocolic resection through McBurney incision
Study NCT01319032 — intervention group
Intervention type: OTHER
Intervention: Extraction of whole blood
Description: Extraction of DNA from whole blood
Study NCT01686152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod Cream, 3.75%
Study NCT01686152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyclara®
Study NCT01686152 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle of Test Product
Study NCT00817648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine
Description: Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
Study NCT00817648 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: risperidone
Description: risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
Study NCT00394563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 25 mcg/kg
Study NCT00394563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 50 mcg/kg
Study NCT04304885 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Sonication method
Description: Sonication dislodges adherent bacteria from explanted prosthetics by ultrasound and may improve the diagnosis of periprosthetic joint infection.
Study NCT04132635 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial dermis
Description: artificial dermis will be used after fully debridement of the wound
Study NCT04132635 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: growth factor
Description: growth factor
Study NCT00539617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Tarceva single agent therapy: 150 mg/day PO
Study NCT00539617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
Study NCT00539617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 400 mg/m2 IV once every 2 weeks for 16 weeks
Study NCT00539617 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85 mg/m2 IV once every 2 weeks for 16 weeks
Study NCT02410824 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stenfilcon A toric lens
Description: toric contact lens
Study NCT02410824 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A toric lens
Description: toric contact lens
Study NCT02084238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
Study NCT03146780 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional impression
Description: A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays).
Study NCT03146780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Scan 1
Description: Direct intra-oral digital scans using Sirona Omnicam software.
Study NCT03146780 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Scan 2
Description: Direct intra-oral digital scans using Planmeca Planscan software.
Study NCT00394563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 100 mcg/kg
Study NCT00394563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RN624 (PF-04383119)
Description: 200 mcg/kg